STERIS Irish FinCo Launches Two-Series Senior Notes to Fund $2.1B Xodus Deal
STE sits 28% above its 52-week low of $195.14 on light trading volume (0.1× avg).
Summary
STERIS Irish FinCo is marketing two series of senior unsecured notes to help fund the $2.1 billion Xodus Medical acquisition, with a 101% special mandatory redemption if the deal falls through. Terms and pricing are not yet set.
Key Events · Financing and Capital Events · STE
-
Two-Series Senior Notes Offered
STERIS Irish FinCo Unlimited Company is offering two series of senior unsecured notes, fully and unconditionally guaranteed by STERIS plc, STERIS Corporation and STERIS Limited. Principal amounts, coupons and maturities are left blank in this preliminary prospectus supplement.
-
Proceeds Fund Xodus Acquisition
Net proceeds, together with a $500 million delayed draw term loan and cash on hand, will fund the $2.1 billion cash Purchase Price for Xodus Medical plus transaction expenses and working capital. The offering is not conditioned on the Acquisition closing.
-
101% Special Mandatory Redemption
If the Acquisition is not completed by the later of January 11, 2028 and five business days after any extended Outside Date, or the Purchase Agreement is terminated, the notes must be redeemed at 101% of principal plus accrued interest.
-
Structural Subordination to Non-Guarantors
Non-guarantor subsidiaries other than the Issuer represented approximately 69% of total assets and carried $1,238 million of liabilities, all structurally senior to the notes. The indenture contains no financial covenants.
Analysis · STE · Unknown
STERIS is selling senior unsecured notes through its Irish financing subsidiary to fund the $2.1 billion cash purchase of Xodus Medical, alongside a $500 million delayed draw term loan and cash on hand. Because the notes carry a 101% special mandatory redemption if the deal does not close by the outside date, bondholders are effectively underwriting deal completion risk. Dollar amounts, coupons and maturities are blank in this preliminary filing, so the actual cost of debt and total leverage are not yet known. This is debt, not equity, so there is no share dilution; the trade-off is higher leverage on a company that already carries roughly $1.9 billion of debt.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STE was trading at $250.73 on NYSE in the Unknown sector, with a market capitalization of approximately $24.4B. The 52-week trading range was $195.14 to $269.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.